Welcome to the p53Lab

ImageThe p53 lab is focusing on the development of new therapies, new diagnostics and new discoveries in the p53 pathway. 11 Million people living with cancer have specific mutations in the p53 gene leading to the production of a faulty p53 protein. This is half the cases of human cancer. In those that have an apparently normal p53 gene we believe that there are faults in the p53 pathway. We are using a variety of approaches to translate this extraordinary finding into clinical benefit. We work closely with many other groups both in Singapore and in the rest of the world to achieve this. We are using biochemical, biophysical, cell biological and genetic approaches in our work and offer an outstanding international training environment

7th Antibody Symposium

Nov 23, 2020  10am - 4pm

You are cordially invited to the 7th Antibody Symposium. The Antibody Symposium is a full day program of interesting talks with industry participation and is jointly organized Chugai Pharmabody Research Pte Ltd and p53Lab, A*STAR.

7th Antibody Symposium Zoom Webinar Registration. Speakers include scientists from Chugai Pharmabody Research, DSO, SIgN, SRIS, p53Lab and Keynote speaker from the Karolinska Institute, Stockholm.

See below for the schedule:

Find out more about exciting new developments in antibodies at Chugai Pharmabody Research from their website or the brochure below.




Upcoming Conferences


  • Nov 23 - 7th Antibody Symposium Zoom Webinar. Speakers include scientists from Chugai Pharmabody Research, DSO, SIgN, SRIS, p53Lab and Keynote speaker from Karolinska Institute, Stockholm. See more details above.


Current Publications

Johansson P, Krona C, Kundu S, Doroszko M, Baskaran S, Schmidt L, Vinel C, Almstedt E, Elgendy R, Elfineh L, Gallant C, Lundsten S, Ferrer Gago FJ, Hakkarainen A, Sipilä P, Häggblad M, Martens U, Lundgren B, Frigault MM, Lane DP, Swartling FJ, Uhrbom L, Nestor M, Marino S, Nelander S (2020). A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma. Cell Rep. 2020 Jul 14;32(2):107897. doi: 10.1016/j.celrep.2020.107897.

Gault J, Liko I, Landreh M, Shutin D, Bolla JR, Jefferies D, Agasid M, Yen HY, Ladds MJGW, Lane DP, Khalid S, Mullen C, Remes PM, Huguet R, McAlister G, Goodwin M, Viner R, Syka JEP, Robinson CV (2020). Combining Native and 'Omics' Mass Spectrometry to Identify Endogenous Ligands Bound to Membrane Proteins. Nat Methods. 2020 May;17(5):505-508. doi: 10.1038/s41592-020-0821-0.

Kong LR, Ong RW, Tan TZ, Mohamed Salleh NAB, Thangavelu M, Chan JV, Koh LYJ, Periyasamy G, Lau JA, Le TBU, Wang L, Lee M, Kannan S, Verma CS, Lim CM, Chng WJ, Lane DP, Venkitaraman A, Hung HT, Cheok CF, Goh BC (2020). A Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation . Nat Commun. 2020 Apr 29;11(1):2086. doi: 10.1038/s41467-020-15608-y.

Popova G, Ladds MJGW, Johansson L, Saleh A, Larsson J, Sandberg L, Sahlberg SH, Qian W, Gullberg H, Garg N, Gustavsson AL, Haraldsson M, Lane D, Yngve U, Lain S (2020). Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.. J Med Chem. 2020 Apr 23;63(8):3915-3934. doi: 10.1021/acs.jmedchem.9b01658.

Sedimbi SK, Hägglöf T, Garimella MG, Wang S, Duhlin A, Coelho A, Ingelshed K, Mondoc E, Malin SG, Holmdahl R, Lane DP, Leadbetter EA, Karlsson MCI (2020). Combined Proinflammatory Cytokine and Cognate Activation of Invariant Natural Killer T Cells Enhances anti-DNA Antibody Responses. Proc Natl Acad Sci U S A. 2020 Apr 21;117(16):9054-9063. doi: 10.1073/pnas.1920463117.

Lundsten S, Hernández VA, Gedda L, Sarén T, Brown CJ, Lane DP, Edwards K, Nestor M (2020). Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 With PEG-Stabilized Lipodisks. Nanomaterials (Basel). 2020 Apr 19;10(4):783. doi: 10.3390/nano10040783.

Mortensen ACL, Morin E, Brown CJ, Lane DP, Nestor M (2020). Enhancing the Therapeutic Effects of in Vitro Targeted Radionuclide Therapy of 3D Multicellular Tumor Spheroids Using the Novel Stapled MDM2/X-p53 Antagonist PM2. EJNMMI Res. 2020 Apr 16;10(1):38. doi: 10.1186/s13550-020-0613-7.

Lim S, Khoo R, Peh KM, Teo J, Chang SC, Ng S, Beilhartz GL, Melnyk RA, Johannes CW, Brown CJ, Lane DP, Henry B, Partridge AW (2020). bioPROTACs as Versatile Modulators of Intracellular Therapeutic Targets Including Proliferating Cell Nuclear Antigen (PCNA). Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5791-5800. doi: 10.1073/pnas.1920251117.

Bolla JR, Corey RA, Sahin C, Gault J, Hummer A, Hopper JTS, Lane DP, Drew D, Allison TM, Stansfeld PJ, Robinson CV, Landreh M (2020). A Mass-Spectrometry-Based Approach to Distinguish Annular and Specific Lipid Binding to Membrane Proteins. Angew Chem Int Ed Engl. 2020 Feb 24;59(9):3523-3528. doi: 10.1002/anie.201914411.

Ling WL, Ng YL, Wipat A, Lane DP, Gan SK (2020). The Quantification of Antibody Elements and Receptors Subunit Expression Using qPCR: The Design of VH, VL, CH, CL, FcR Subunits Primers for a More Holistic View of the Immune System. J Immunol Methods. 2020 Jan;476:112683. doi: 10.1016/j.jim.2019.112683.

Ferrer-Gago FJ, Koh LQ, Lane DP (2020). Functionalized Resins for the Synthesis of Peptide Alcohols. Chemistry. 2020 Jan 7;26(2):379-383. doi: 10.1002/chem.201903965.

Diller DJ, Swanson J, Bayden AS, Brown CJ, Thean D, Lane DP, Partridge AW, Sawyer TK, Audie J (2019). Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides. Molecules. Dec 14; 24(24). doi: 10.3390/molecules24244586

Frosi Y, Inoue K, Ramlan SR, Lane DP, Watanabe T and Brown CJ (2019). Simultaneous measurement of p53:Mdm2 and p53:Mdm4 protein-protein interactions in whole cells using fluorescence labelled foci. Sci Rep. 2019 Nov 29;9(1):17933. doi: 10.1038/s41598-019-54123-z.

Kannan S, Partridge AW, Lane DP, Verma CS (2019). The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors. Int J Mol Sci. Nov 28;20(23):5996. doi: 10.3390/ijms20235996.

Xue Y, San Luis B, Lane DP. (2019). Intratumour heterogeneity of p53 expression; causes and consequences. J Pathol. Nov;249(3):274-285. doi: 10.1002/path.5328.

Koh XY, Koh XH, Hwang LA, Ferrer FJ, Rahmat SAB, Lama D, Lane DP (2019). Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase. Oncogene. Nov;38(48):7342-7356.

Mortensen ACL, Spiegelberg D, Brown CJ, Lane DP, Nestor M (2019). The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells. Front Oncol. 2019 Sep 19;9:923. doi: 10.3389/fonc.2019.00923. eCollection 2019.